Lifevantage (LFVN) Competitors $12.58 +0.03 (+0.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.57 -0.01 (-0.08%) As of 08/1/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. MRVI, MGTX, PHAT, AUTL, XNCR, VALN, RLAY, BCAX, ORGO, and SEPNShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include Maravai LifeSciences (MRVI), MeiraGTx (MGTX), Phathom Pharmaceuticals (PHAT), Autolus Therapeutics (AUTL), Xencor (XNCR), Valneva (VALN), Relay Therapeutics (RLAY), Bicara Therapeutics (BCAX), Organogenesis (ORGO), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors Maravai LifeSciences MeiraGTx Phathom Pharmaceuticals Autolus Therapeutics Xencor Valneva Relay Therapeutics Bicara Therapeutics Organogenesis Septerna Lifevantage (NASDAQ:LFVN) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings. Which has more volatility & risk, LFVN or MRVI? Lifevantage has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Is LFVN or MRVI more profitable? Lifevantage has a net margin of 4.12% compared to Maravai LifeSciences' net margin of -67.14%. Lifevantage's return on equity of 34.67% beat Maravai LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.12% 34.67% 15.24% Maravai LifeSciences -67.14%-12.91%-6.87% Which has preferable earnings & valuation, LFVN or MRVI? Lifevantage has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$200.16M0.79$2.94M$0.6918.23Maravai LifeSciences$259.18M2.18-$144.85M-$1.14-1.95 Do insiders and institutionals hold more shares of LFVN or MRVI? 35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 20.7% of Lifevantage shares are owned by company insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts recommend LFVN or MRVI? Lifevantage currently has a consensus price target of $30.50, suggesting a potential upside of 142.45%. Maravai LifeSciences has a consensus price target of $6.64, suggesting a potential upside of 199.05%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media prefer LFVN or MRVI? In the previous week, Maravai LifeSciences had 7 more articles in the media than Lifevantage. MarketBeat recorded 7 mentions for Maravai LifeSciences and 0 mentions for Lifevantage. Maravai LifeSciences' average media sentiment score of 0.70 beat Lifevantage's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Overall Sentiment Lifevantage Neutral Maravai LifeSciences Positive SummaryLifevantage beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.98M$15.88B$5.48B$9.54BDividend Yield1.43%1.47%4.73%4.09%P/E Ratio18.2318.7528.8623.83Price / Sales0.792.21371.7266.14Price / Cash14.2316.4435.4557.96Price / Book6.143.558.275.54Net Income$2.94M$430.42M$3.25B$259.28M7 Day Performance-8.24%-6.02%-3.73%-4.68%1 Month Performance-6.12%-3.94%4.29%4.36%1 Year Performance50.66%16.66%25.87%17.89% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage3.7998 of 5 stars$12.58+0.2%$30.50+142.4%+55.9%$157.98M$200.16M18.23260MRVIMaravai LifeSciences3.7437 of 5 stars$2.65-1.5%$6.64+150.5%-76.9%$685.03M$259.18M-2.32610Positive NewsUpcoming EarningsMGTXMeiraGTx4.433 of 5 stars$8.23-1.7%$24.00+191.6%+56.8%$672.66M$33.28M-3.55300News CoveragePHATPhathom Pharmaceuticals2.668 of 5 stars$8.80-8.6%$17.50+98.9%-26.9%$672.31M$81.86M-1.68110Upcoming EarningsAUTLAutolus Therapeutics2.3377 of 5 stars$2.51-0.4%$9.32+271.3%-47.9%$670.68M$10.12M-2.85330XNCRXencor3.4785 of 5 stars$9.03-2.3%$28.00+210.1%-59.9%$657.62M$110.49M-2.95280News CoverageUpcoming EarningsShort Interest ↑VALNValneva2.5642 of 5 stars$7.61-0.9%$15.50+103.7%+2.4%$653.52M$183.52M-6.39700Gap DownHigh Trading VolumeRLAYRelay Therapeutics1.9492 of 5 stars$3.70-1.1%$17.67+377.5%-57.9%$641.20M$7.68M-1.66330News CoverageUpcoming EarningsBCAXBicara TherapeuticsN/A$11.81+0.5%$31.86+169.8%N/A$640.80MN/A0.0032Positive NewsORGOOrganogenesis4.0119 of 5 stars$5.02-0.2%$6.50+29.5%+62.2%$638.07M$482.04M-29.53950Upcoming EarningsSEPNSepterna1.3689 of 5 stars$13.83-0.4%$26.75+93.4%N/A$618.47M$1.08M0.00N/A Related Companies and Tools Related Companies Maravai LifeSciences Competitors MeiraGTx Competitors Phathom Pharmaceuticals Competitors Autolus Therapeutics Competitors Xencor Competitors Valneva Competitors Relay Therapeutics Competitors Bicara Therapeutics Competitors Organogenesis Competitors Septerna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
